Age, yrs, mean ± SD | 65.5 ± 14 |
Sex | |
Female | 53 (88.3) |
Male | 7 (11.7) |
Subset | |
Limited | 40 (66.7) |
Diffuse | 20 (33.3) |
RP duration, yrs, mean ± SD | 22.6 ± 13.4 |
Disease duration, yrs, mean ± SD | 15.3 ± 8.7 |
Autoantibodies | |
ACA | 24 (40) |
Scl70 | 23 (38.3) |
ACA + Scl70 | 2 (3.3) |
Other | 11 (18.4) |
Videocapillaroscopy | |
Early | 9 (15) |
Active | 18 (30) |
Late | 33 (55) |
mRSS | 9.8 ± 10.2 |
Smokers | |
Yes | 7 (11.7) |
No | 48 (80) |
Ex-smoker | 5 (8.3) |
Arterial hypertension | 31 (51.7) |
Hypercholesterolemia | |
Increased total cholesterol | 10 (16.7) |
Increased LDL cholesterol | 20 (33.3) |
Low HDL cholesterol | 9 (15) |
Hypertriglyceridemia | 10 (16.7) |
Diabetes mellitus | 2 (3.3) |
Intermittent claudication | 10 (16.8) |
Upper limb ulcers | 48 (80) |
Ulcers in the other sites | 14 (23.3) |
Calcinosis | 22 (36.7) |
Gastrointestinal involvement | 60 (100) |
GERD | 60 (100) |
Other | 9 (15) |
Interstitial lung disease | 32 (53.3) |
Pulmonary arterial hypertension | 9 (15) |
Peripheral arterial disease | 17 (18.3) |
Not hemodynamically significant | 7 (41.2) |
Hemodynamically significant | 10 (58.8) |
Venous insufficiency | 18 (30) |
ACA: anticentromere autoantibodies; mRSS: modified Rodnan skin score; LDL: low-density lipoprotein; HDL: high-density lipoprotein; GERD: gastroesophageal reflux disease; RP: Raynaud phenomenon.